Galapagos is planning to wind down its cell therapy business, completing a whiplash change that saw the biotech go from focusing on the modality to ditching it in six months. Belgium-based Galapagos ...

Ozempic maker Novo Nordisk (NVO) is closing its cell therapy division as part of a major restructuring drive initiated under the company’s new CEO, Mike Doustdar, Bloomberg News reported on Thursday, ...

Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the ...

Redefining the repeating pattern in photonic crystals creates tightly confined pathways for light while preserving symmetry, offering a simple route to ultracompact and low loss light circuits.

Hexagon shares rose after the Swedish measurement-technology group said it agreed to sell its design and engineering business to Cadence Design Systems for 2.7 billion euros ($3.15 billion). Shares in ...

(Reuters) -Cadence Design said on Thursday it will buy the design and engineering business of Stockholm-based Hexagon AB for 2.7 billion euros ($3.16 billion), to expand its customer base and scale up ...

Hexagon AB has faced slow growth and margin pressure in 2025, but profitable segments and recurring revenue continue to expand. The company’s autonomous solutions unit posted strong double-digit ...

Federal IT systems integrator B&A has acquired Hexagon US Federal’s Strategic Services and Solutions, or HS3, business unit as part of a push to expand its capabilities in delivering mission-critical ...

Abstract: To design the frequency selective surface (FSS) with more degrees of freedom (DoFs) and incident angle stability, an improved machine learning-based inverse topological design model is ...